Direct procedure for the production of211At-labeled antibodies with an ε-lysyl-3-(trimethylstannyl)benzamide immunoconjugate

Journal of Nuclear Medicine

Volumn 49, Issue 9, 2008, Pages 1537-1545

  Lindegren, Sture ^a   Frost, Sofia ^a   Bäck, Tom ^a   Haglund, Elin ^a   Elgqvist, Jörgen ^a   Jensen, Holger ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Rigshospitalet   (Denmark)

Author keywords

211At; Astatination; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; ASTATINE 211; EPSILON LYSYL 3 (TRIMETHYLSYANNYL)BENZAMIDE IMMUNOCONJUGATE; N IODOSUCCINIMIDE; N SUCCINIMIDYL 3 (TRIMETHYLSTANNYL)BENZOATE; OXIDIZING AGENT; RADIOISOTOPE; REAGENT; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SCREENING; DRUG UPTAKE; FEMALE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RADIOACTIVITY; RADIOCHEMISTRY; REACTION TIME; TISSUE DISTRIBUTION; TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; BENZAMIDES; FEMALE; IMMUNOCONJUGATES; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 51349138340     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.049833     Document Type: Article

References (39)

1. Palm S, Back T, Claesson I, et al. Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay. Anticancer Res. 1998;18:1671-1676.
2. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 1994;54:4719-4725.
3. 211At in nude mice with intraperitoneally growing ovarian cancer xenografts: a long-term study. Acta Oncol. 2000;39:741-745.
4. 211At. Radiat Res. 2002;157:633-641.
5. Zhang M, Yao Z, Zhang Z, et al. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood. 2006;108:705-710.
6. 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007;34:779-785.
7. Andersson H, Elgqvist J, Horvath G, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res. 2003;9(suppl):3914S-3921S.
8. 211At-labeled radiopharmaceuticals. J Nucl Med. 2001;42:1516-1518.
9. Tolmachev V, Carlsson J, Lundqvist H. A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy: availability of suitable radionuclides. Acta Oncol. 2004;43:264-275.
10. Larsen RH, Bruland OS. Radiolysis of radioimmunoconjugates: reduction in antigen-binding ability by (alpha)-particle radiation. J Labelled Comp Radiopharm. 1995;36:1009-1018.
11. 211At. J Nucl Med. 2007;48:1190-1196.
12. Milius RA, McLaughlin WH, Lambrecht RM, et al. Organoastatine chemistry: astatination via electrophilic destannylation. Int J Rad Appl Instrum [A]. 1986;37:799-802.
13. 211At labeling of humanized anti-Tac. Nucl Med Biol. 2001;28:845-856.
14. Wunderlich G, Franke WG, Doberenz I, Fischer S. Two ways to establish potential At-211 radiopharmaceuticals. Anticancer Res. 1997;17:1809-1813.
15. Wilbur DS, Hadley SW, Hylarides MD, et al. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med. 1989;30:216-226.
16. Zalutsky MR, Narula AS. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Int J Rad Appl Instrum [A]. 1988;39:227-232.
17. Garg PK, Archer GE Jr, Bigner DD, Zalutsky MR. Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling. Int J Rad Appl Instrum [A]. 1989;40:485-490.
18. Wilbur DS, Hamlin DK, Srivastava RR, Chyan MK. Synthesis, radioiodination, and biodistribution of some nido- and closo-monocarbon carborane derivatives. Nucl Med Biol. 2004;31:523-530.
19. Wilbur DS, Chyan MK, Hamlin DK, Vessella RL, Wedge TJ, Hawthorne MF. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Bioconjug Chem. 2007;18:1226-1240.
20. 211At α-particles. J Nucl Med. 2005;46:700-706.
21. 211At- astatobenzoate synthesis. J Nucl Med. 2005;46:1393-1400.
22. Lindegren S, Back T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001;55:157-160.
23. Lindegren S, Andersson H, Back T, Jacobsson L, Karlsson B, Skarnemark G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate. Nucl Med Biol. 2001;28:33-39.
24. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
25. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341-1351.
26. Imam SK. Advancements in cancer therapy with alpha-emitters: a review. Int J Radiat Oncol Biol Phys. 2001;51:271-278.
27. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des. 2000;6:1433-1455.
28. Lambrecht RM, Mirzadeh S. Cyclotron isotopes and radiopharmaceuticals, XXXV: astatine-211. Int J Appl Radiat Isot. 1985;36:443-450.
29. 211At via the 209Bi (alpha,2n)211 at reaction. Appl Radiat Isot. 1996;47:135-143.
30. Visser GWM, Diemer EL, Kaspersen FM. The nature of the astatine-protein bond. Int J Appl Radiat Isot. 1981;32:905-912.
31. White JS, Tobin JM. Inorganic tin and organotin interactions with Candida maltosa. Appl Microbiol Biotechnol. 2004;63:445-451.
32. Visser GWM, Diemer EL. Inorganic astatine chemistry, part II: the chameleon behavior and electrophilicity of At-species. Radiochimica Acta on Astatine Chemistry. 1983;33:97-103.
33. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285-4289.
34. Persson MI, Gedda L, Jensen HJ, Lundqvist H, Malmstrom PU, Tolmachev V. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol Rep. 2006;15:673-680.
35. 111In- labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48:1357-1368.
36. Esteban JM, Schlom J, Gansow OA, et al. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med. 1987;28:861-870.
37. 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol. 2007;34:173-183.
38. 2 fragment. Cancer Res. 1990;50:3514-3520.
39. 211At-labeled monoclonal antibody MX35. J Nucl Med. 2005;46:1907-1915.